Maggie L. Shaw

Individuals with serious mental illness have a greater risk of acquiring HIV compared with the general population and could therefore benefit from preexposure prophylaxis (PrEP) services in the community.

The novel, first-in-class, small molecule prompted high rates of clinical response and molecular remission in patients with oligoblastic acute myeloid leukemia (AML).

Treatment optimization for heart failure with reduced ejection fraction is the focus of the American College of Cardiology’s 2021 update to its 2017 Expert Consensus Decision Pathway on managing patients with the condition.

A 13.9% increase in diagnosed cases of HIV was seen following expansion of Medicaid coverage under the Affordable Care Act.

Higher mortality rates were seen among patients with acute lymphoblastic leukemia (ALL) who were considered obese, in a recent study of patients treated at Mayo Clinic.

Women receiving treatment for early-stage breast cancer may have a lower risk of developing heart failure if their therapy regimens include statins.

Despite outcome improvements for acute lymphoblastic leukemia (ALL), mortality rates remain high, with significant survival disparities seen between Black and White children.

Research findings from Mayo Clinic investigators demonstrate that diabetes did not increase the risk of death among patients with acute or chronic myeloid leukemia.

Both women and men have a greater chance of 90-day hospital readmission when they are considered to be in frail condition from heart failure.

Recipients of hematopoietic stem-cell transplantation (HSCT) who develop coronavirus disease 2019 (COVID-19) may be predisposed to a greater mortality rate if they meet certain disease criteria.

The 62nd American Society of Hematology (ASH) Annual Meeting and Exposition featured leading experts in hematology and covered some of the most cutting-edge research in the field.

Exciting new and ongoing developments in chimeric antigen receptor (CAR) T-cell therapies were covered at the 62nd American Society of Hematology (ASH) annual meeting.

Severe mental illnesses that precede a breast cancer diagnosis may increase the risk of both all-cause and cancer-specific mortality among women with Medicaid coverage.

Tyrosine kinase inhibitor (TKI) therapy enables patients with chronic myeloid leukemia (CML) to reach life expectancies equivalent to the general population and treatment-free remission, but quality of life can deteriorate with treatment.

A comparison of 3 levels of SARS-CoV-2 antibodies in convalescent plasma shows that the 30-day death rate was lowest in the group receiving high-titer plasma.

Use of the RNA inhibitor givosiran was shown to reduce expression of delta-aminolevulinic acid synthase 1, in turn reducing the severity of acute attacks and chronic symptoms for patients with severe hepatic porphyria.

A more aggressive tumor microenvironment may be to blame for the exaggerated inflammatory response more often seen in Black women with breast cancer compared with White women.

The FDA today accepted Boehringer Ingelheim and Eli Lilly’s supplemental New Drug Application for Jardiance (empagliflozin), the sodium glucose co-transporter 2 inhibitor being investigated for use in patients with heart failure.

A recent meta-analysis appearing in Journal of Cancer indicates a connection between minimal residual disease (MRD)–positive status and worse progression-free survival (PFS) and overall survival (OS) following induction and consolidation therapies.

Age, renal disease, and suboptimal myeloma control were among the many factors identified in a recent study as increasing the risk of death from coronavirus disease 2019 (COVID-19) for patients being treated for multiple myeloma (MM).

An abstract from last month’s San Antonio Breast Cancer Symposium identifies factors linked with longer-term controlled substance use after treatment of breast cancer with mastectomy plus breast reconstruction in women receiving opioids, benzodiazepines, and other sedative/hypnotics.

Recent study findings highlight mixed results following use of this medication among Mississippi and Massachusetts Medicaid beneficiaries.

Our top heart failure articles of the year cover a groundbreaking development for dapagliflozin, address the important issue of disparities in this space, and see coronavirus disease 2019 make yet another appearance.

The FDA has approved Margenza (margetuximab-cmkb) plus chemotherapy as a treatment option for adults with HER2-postive advanced breast cancer.

Hoping to improve outcomes among patients with acute heart failure discharged from the emergency department, study findings show that 30-day improvements from a self-care intervention were not sustainable through 90 days.

Four of our top 5 HIV articles for 2020 saw the HIV pandemic overlap with the coronavirus disease 2019 pandemic and had Anthony Fauci, MD, in common. The fifth is from this year's AIDS 2020 virtual conference, itself a product of the overlapping pandemics.

These top 5 posts from our breast cancer compendium in 2020 show that while much is known about breast cancer, much remains that can help to broaden the knowledge armamentarium.

At the recent meeting of the American Society of Hematology, results from several studies involved the use of chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma.

Four principal themes emerged in this study, describing why Latino/a and Black transgender women and men who have sex with men discontinued their preexposure prophylaxis (PrEP) to prevent HIV.

A 5-phase program designed to increase knowledge among patients with heart failure has shown promise in more effective disease management and hospital readmission reduction.